search
Back to results

Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO)

Primary Purpose

Congenital Diaphragmatic Hernia

Status
Enrolling by invitation
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
BALT GOLDBALL 2 detachable latex ballon
BALTACCIBDPE100 Microcatheter
Storz fetoscopic operating sheath and miniature telescope/fetoscope
Sponsored by
Mauro H. Schenone
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Congenital Diaphragmatic Hernia

Eligibility Criteria

18 Years - 50 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Singleton pregnancy Normal fetal karyotype or microarray. Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is > 26 weeks Isolated severe left CDH with O/E LHR < 25% ) Gestation age at enrollment prior to 29 wks plus 6 days. Pulmonary hypoplasia with ultrasound O/E LHR < 25% (measured at 18 0/7 to 29 5/7 weeks) at the time of surgery. Gestational age at FETO procedure 27 weeks 0 days to 29 weeks 6 days as determined by clinical information (LMP) and evaluation of first ultrasound Patient meets psychosocial criteria: able to reside within 30 minutes of Mayo Clinic, Rochester and able to comply with the travel for the follow-up requirements of the trial; patient has a support person (e.g. spouse, partner, mother) available to stay with the patient for the duration of the pregnancy at Mayo Clinic Patient is willing and able to give informed consent Appropriate multi-disciplinary counseling performed with maternal-fetal medicine, neonatology, pediatric surgery, genetics, pediatric otolaryngology (ENT) Exclusion Criteria: Multi-fetal pregnancy History of natural rubber latex allergy Preterm labor, cervix shortened (<20 mm) at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor Psychosocial ineligibility, precluding consent: inability to reside within 30 minutes of Mayo Clinic, Rochester and inability to comply with the travel for the follow-up requirements of the trial; patient does not have a support person (e.g. spouse, partner, mother) available to stay with the patient for the duration of the pregnancy at Mayo Clinic Right sided CDH or bilateral CDH, isolated left sided with O/E LHR >25% measured at 18 0/7 to 29 6/7 weeks) as determined by ultrasound Additional fetal anomaly and chromosomal abnormalities by ultrasound, MRI, or echocardiogram that will significantly worsen prognosis. No cases will be removed post hoc if abnormalities are discovered in the course of post-operative monitoring Maternal contraindication to fetoscopic surgery History of incompetent cervix with or without cerclage Placental abnormalities (previa, abruption, accreta) known at time of enrollment Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy Maternal HIV, Hepatitis-B, Hepatitis-C status positive. Uterine anomaly such as large or multiple fibroids or mullerian duct abnormality that will make the procedure technically unfeasible No safe or technically feasible fetoscopic approach to balloon placement Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy

Sites / Locations

  • Mayo Clinic Minnesota

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

FETO Group

Arm Description

Participants will undergo fetal endoscopic tracheal occlusion (FETO) surgical procedure between 27 weeks 0 days and 29 weeks 6 days gestation.

Outcomes

Primary Outcome Measures

Technical success of the balloon placement procedure
The number of successful balloon placement procedures defined as balloon was correctly inflated and placed/secured in the trachea.
Technical success of balloon retrieval procedure
The number of successful balloon retrieval procedure defined as antenatal removal of the balloon.
Operative times
FETO placement and release operative times reported in minutes
Frequency of unplanned balloon removal
The frequency of non-emergent and emergent completion of FETO release (unplanned balloon removal)
Number of incidences of maternal complications
Maternal complications including preterm labor, premature rupture of membranes, oligohydramnios, polyhydramnios, chorioamnionitis
Gestational Age at Delivery
Gestation Age reported at time of delivery

Secondary Outcome Measures

Fetal Lung Growth as measured via Fetal Lung Volume
Fetal Lung Volume as measured via ultrasound
Fetal Lung Growth as measured via LHR
Lung area to head circumference Ratio (LHR) as measured via ultrasound
Fetal Survival
Survival at 30 days, discharge from the hospital and at 6 months if still hospitalized
Fetal Oxygen Dependency
Oxygen dependency graded as none, mild, moderate, severe as assessed by treating physician
Occurrence of severe pulmonary hypertension
Number of occurrence of severe pulmonary hypertension in infants based on echocardiogram
ECMO Support
Number of infants reported that required Extracorporeal membrane oxygenation (ECMO) support
Number of days in NICU
Number of days infant was in neonatal intensive care unit
Number of days of ventilator support
Number of reported days infants required ventilator support
Number of periventricular leukomalacia at < 2 months postnatally
Number of infants reported presence of periventricular leukomalacia at < 2 months postnatally
Number of infant complications
Number of infants reporting the presence of: neonatal sepsis, intraventricular hemorrhage (grade 3 or higher), retinopathy of prematurity (grade 3 or higher) or gastro-esophageal reflux
Use of patch or muscle flap
Number of infants reported to require the use of patch or muscle flap
Maternal hospitalization
Number of reported days of maternal hospitalization
Route of delivery
Number of participants that delivered vaginally and via caesarean section

Full Information

First Posted
July 17, 2023
Last Updated
August 7, 2023
Sponsor
Mauro H. Schenone
search

1. Study Identification

Unique Protocol Identification Number
NCT05962346
Brief Title
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
Acronym
FETO
Official Title
Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion for Severe Left Congenital Diaphragmatic Hernia
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
September 2023 (Anticipated)
Primary Completion Date
July 2043 (Anticipated)
Study Completion Date
July 2043 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Mauro H. Schenone

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this research is to gather information on the safety and effectiveness of a procedure called Fetoscopic Endoluminal Tracheal Occlusion (FETO) at Mayo Clinic. The intent of the FETO procedure is to improve development of the lungs in fetuses diagnosed with severe congenital diaphragmatic hernia (CDH).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Congenital Diaphragmatic Hernia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
FETO Group
Arm Type
Experimental
Arm Description
Participants will undergo fetal endoscopic tracheal occlusion (FETO) surgical procedure between 27 weeks 0 days and 29 weeks 6 days gestation.
Intervention Type
Device
Intervention Name(s)
BALT GOLDBALL 2 detachable latex ballon
Intervention Description
Inflated with fluid in the fetal trachea and provide with the occlusion necessary to promote lung growth.
Intervention Type
Device
Intervention Name(s)
BALTACCIBDPE100 Microcatheter
Intervention Description
Used to deliver the detachable balloon
Intervention Type
Device
Intervention Name(s)
Storz fetoscopic operating sheath and miniature telescope/fetoscope
Intervention Description
Used to percutaneously enter though the maternal abdominal wall, uterus and into the amniotic cavity, fetal mouth, pharynx, larynx, into the trachea where the delivery catheter will be used to deliver the detachable balloon that will provide with the tracheal occlusion.
Primary Outcome Measure Information:
Title
Technical success of the balloon placement procedure
Description
The number of successful balloon placement procedures defined as balloon was correctly inflated and placed/secured in the trachea.
Time Frame
Up to 29 weeks gestation
Title
Technical success of balloon retrieval procedure
Description
The number of successful balloon retrieval procedure defined as antenatal removal of the balloon.
Time Frame
Up to 34 weeks gestation
Title
Operative times
Description
FETO placement and release operative times reported in minutes
Time Frame
Up to 34 weeks gestation
Title
Frequency of unplanned balloon removal
Description
The frequency of non-emergent and emergent completion of FETO release (unplanned balloon removal)
Time Frame
Up to 34 weeks gestation
Title
Number of incidences of maternal complications
Description
Maternal complications including preterm labor, premature rupture of membranes, oligohydramnios, polyhydramnios, chorioamnionitis
Time Frame
Up to 41 weeks gestation
Title
Gestational Age at Delivery
Description
Gestation Age reported at time of delivery
Time Frame
Up to 41 weeks gestation
Secondary Outcome Measure Information:
Title
Fetal Lung Growth as measured via Fetal Lung Volume
Description
Fetal Lung Volume as measured via ultrasound
Time Frame
Up to 24 months post partum
Title
Fetal Lung Growth as measured via LHR
Description
Lung area to head circumference Ratio (LHR) as measured via ultrasound
Time Frame
Up to 24 months post partum
Title
Fetal Survival
Description
Survival at 30 days, discharge from the hospital and at 6 months if still hospitalized
Time Frame
Up to 6 months post partum
Title
Fetal Oxygen Dependency
Description
Oxygen dependency graded as none, mild, moderate, severe as assessed by treating physician
Time Frame
Up to 24 months post partum
Title
Occurrence of severe pulmonary hypertension
Description
Number of occurrence of severe pulmonary hypertension in infants based on echocardiogram
Time Frame
Up to 24 months post partum
Title
ECMO Support
Description
Number of infants reported that required Extracorporeal membrane oxygenation (ECMO) support
Time Frame
Up to 24 months post partum
Title
Number of days in NICU
Description
Number of days infant was in neonatal intensive care unit
Time Frame
Up to 24 months post partum
Title
Number of days of ventilator support
Description
Number of reported days infants required ventilator support
Time Frame
Up to 24 months post partum
Title
Number of periventricular leukomalacia at < 2 months postnatally
Description
Number of infants reported presence of periventricular leukomalacia at < 2 months postnatally
Time Frame
Up to 2 months post partum
Title
Number of infant complications
Description
Number of infants reporting the presence of: neonatal sepsis, intraventricular hemorrhage (grade 3 or higher), retinopathy of prematurity (grade 3 or higher) or gastro-esophageal reflux
Time Frame
Up to 24 months post partum
Title
Use of patch or muscle flap
Description
Number of infants reported to require the use of patch or muscle flap
Time Frame
Up to 24 months post partum
Title
Maternal hospitalization
Description
Number of reported days of maternal hospitalization
Time Frame
Up to 24 months post partum
Title
Route of delivery
Description
Number of participants that delivered vaginally and via caesarean section
Time Frame
Day 1 (post partum)

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Singleton pregnancy Normal fetal karyotype or microarray. Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is > 26 weeks Isolated severe left CDH with O/E LHR < 25% ) Gestation age at enrollment prior to 29 wks plus 6 days. Pulmonary hypoplasia with ultrasound O/E LHR < 25% (measured at 18 0/7 to 29 5/7 weeks) at the time of surgery. Gestational age at FETO procedure 27 weeks 0 days to 29 weeks 6 days as determined by clinical information (LMP) and evaluation of first ultrasound Patient meets psychosocial criteria: able to reside within 30 minutes of Mayo Clinic, Rochester and able to comply with the travel for the follow-up requirements of the trial; patient has a support person (e.g. spouse, partner, mother) available to stay with the patient for the duration of the pregnancy at Mayo Clinic Patient is willing and able to give informed consent Appropriate multi-disciplinary counseling performed with maternal-fetal medicine, neonatology, pediatric surgery, genetics, pediatric otolaryngology (ENT) Exclusion Criteria: Multi-fetal pregnancy History of natural rubber latex allergy Preterm labor, cervix shortened (<20 mm) at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor Psychosocial ineligibility, precluding consent: inability to reside within 30 minutes of Mayo Clinic, Rochester and inability to comply with the travel for the follow-up requirements of the trial; patient does not have a support person (e.g. spouse, partner, mother) available to stay with the patient for the duration of the pregnancy at Mayo Clinic Right sided CDH or bilateral CDH, isolated left sided with O/E LHR >25% measured at 18 0/7 to 29 6/7 weeks) as determined by ultrasound Additional fetal anomaly and chromosomal abnormalities by ultrasound, MRI, or echocardiogram that will significantly worsen prognosis. No cases will be removed post hoc if abnormalities are discovered in the course of post-operative monitoring Maternal contraindication to fetoscopic surgery History of incompetent cervix with or without cerclage Placental abnormalities (previa, abruption, accreta) known at time of enrollment Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy Maternal HIV, Hepatitis-B, Hepatitis-C status positive. Uterine anomaly such as large or multiple fibroids or mullerian duct abnormality that will make the procedure technically unfeasible No safe or technically feasible fetoscopic approach to balloon placement Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mauro Schenone, MD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic Minnesota
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://www.mayo.edu/research/clinical-trials
Description
Mayo Clinic Clinical Trials

Learn more about this trial

Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

We'll reach out to this number within 24 hrs